With the novel coronavirus spreading both fear and illness across the world, it is a worthwhile exercise to look at the patent landscape of antiviral vaccines. By analyzing both the quality and quantity of the patent portfolios of the world’s leading manufacturers and researchers, it is possible to evaluate the companies and research institutes that are at the forefront of finding vaccines and cures for potentially deadly viral diseases.
Join Gene Quinn, President, and CEO of IPWatchdog, Inc, along with William Mansfield, Head of Consulting and Customer Success at LexisNexis® PatentSight®, on THURSDAY, April 2, 2020, at 12 pm (noon) EST to learn more about:
- The entire technology field and key players in antiviral vaccine market
- Review of selected companies who have technologies related to coronavirus
- Portfolio landscaping of global pharma leaders in this technology field
- How PatentSight metrics evaluate the portfolio strength